Mirtazapin Bluefish (Mirtazapine)

Mirtazapine acts within the central nervous system to alleviate depressive symptoms and is indicated for conditions within the depressive disorder spectrum.

• Major depressive disorder: reduces depressive mood, improves energy and interest.
• Treatment‑resistant depression: provides an alternative mechanism when other agents fail.
• Depression with insomnia: promotes sleep while improving mood.

• Mirtazapine antagonizes central presynaptic α2‑adrenergic receptors, thereby increasing norepinephrine release, and blocks serotonin 5‑HT2 and 5‑HT3 receptors as well as histamine H1 receptors. This combined activity enhances serotonergic and noradrenergic neurotransmission while producing sedative effects, contributing to its antidepressant action.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Sedation or drowsiness
• Increased appetite and weight gain
• Dry mouth
• Constipation
• Dizziness
• Orthostatic hypotension

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia
• Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)
• Suicidal ideation or behavior worsening
• Serotonin syndrome when combined with other serotonergic agents
• Hepatic dysfunction
• Unexplained bleeding or bruising

Before initiating therapy, clinicians should consider several safety aspects.

• Monitor weight: patients may experience increased appetite and weight gain, requiring regular BMI checks.
• Assess suicidality: screen for worsening depression or emergent suicidal thoughts, especially early in treatment.
• Caution in hepatic impairment: dose adjustment may be needed for patients with liver dysfunction.
• Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal risk.
• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with several drug classes, necessitating careful management.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use may cause hypertensive crisis or serotonin syndrome.
• CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.
• Other serotonergic agents (e.g., SSRIs, SNRIs, triptans): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels.
• Alcohol: can enhance sedative effects and impair cognition.
• Anticholinergic drugs: may increase dry mouth and constipation.